Meeting
2020 Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
Authors
Aly-Khan A. Lalani
Juravinski Cancer Centre, McMaster University, Hamilton, ON, Canada
Aly-Khan A. Lalani , Anand Swaminath , Gregory Russell Pond , Anil Kapoor , William Chu , Jonathan L. Bramson , Michael G. Surette , Mark Norman Levine , Sebastien J. Hotte
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Trials in Progress Poster Session
Session Title
Trials in Progress Poster Session C: Renal Cell Cancer
Track
Renal Cell Cancer
Sub Track
Therapeutics
Clinical Trial Registration Number
NCT04090710
Citation
J Clin Oncol 38, 2020 (suppl 6; abstr TPS761)
Abstract #
TPS761
Poster Bd #
K17
Abstract Disclosures
Similar Posters
Poster
2023 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani
Poster
2022 ASCO Genitourinary Cancers Symposium
Phase II trial of cytoreductive stereotactic hypofractionated radiotherapy with combination ipilimumab/nivolumab for metastatic kidney cancer (CYTOSHRINK).
First Author: Aly-Khan A. Lalani
Poster
2023 ASCO Annual Meeting
Role of cytoreductive nephrectomy (CN) in metastatic clear cell renal cell carcinoma (mccRCC) in the era of immunotherapy (IO): An analysis of the National Cancer Database (NCDB).
First Author: Maroun Bou Zerdan
Poster
2023 ASCO Gastrointestinal Cancers Symposium
Randomized phase 2 study of nivolumab with or without ipilimumab combined with stereotactic body radiotherapy in pretreated patients with metastatic biliary tract cancer.
First Author: Alice Markussen